Company News

    RSS Feed

Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

January 22, 2018 | Acasti Pharma (NASDAQ:ACST) a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares have given notice  … Read More

ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872

January 22, 2018 | ChemoCentryx (Nasdaq:CCXI) announced today positive overall survival results from an ongoing Phase Ib clinical trial of the Company’s second CCR2 inhibitor – CCX872 – in the treatment of locally advanced/metastatic pancreatic cancer.

As quoted in the press release:
“The positive findings from our pancreatic cancer trial demonstrate that improved patient survival could  … Read More

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

January 22, 2018 | Stemline Therapeutics (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to offer and sell, subject to market conditions, 3,700,000 shares of its common stock in an underwritten public offering.

As quoted in the press release:
Stemline intends to use the net proceeds from this offering for  … Read More

Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients

January 22, 2018 | Novartis (VTX:NOVN) announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334) 140mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

As quoted in the press release:
“The  … Read More

Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura

January 22, 2018 | Anthera Pharmaceuticals (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency.

As quoted in the press release:
“The positive interim futility analysis of the RESULT study represents one of the last clinical  … Read More

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

January 22, 2018 | Astellas Pharma (TSE:4503) and Vical (NASDAQ:VICL) announced that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus-seropositive hematopoietic stem cell transplant recipients, did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. The vaccine was generally well tolerated, with injection-site reactions being the most commonly reported  … Read More

Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate

January 22, 2018 | Nymox Pharmaceutical (NASDAQ:NYMX) reported today top-line 5-year results from Nymox’s U.S. Study NX03-0040. Study NX03-0040 was undertaken starting in 2012 at 44 investigational sites across the U.S. comprising a highly representative sample of 146 men with the biopsy confirmed diagnosis of T1c prostate cancer, which is the most common type  … Read More